Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial ; volume:55 ; number:9 ; day:6 ; month:3 ; year:2023 ; pages:2321-2326 ; date:9.2023
International urology and nephrology ; 55, Heft 9 (6.3.2023), 2321-2326, 9.2023
- Creator
-
Hammad, Hany
Shaaban, Asmaa
Philips, Mariana Victor
Fayed, Ahmed
Abdelaziz, Tarek Samy
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11255-023-03539-8
- URN
-
urn:nbn:de:101:1-2023110208131695440077
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hammad, Hany
- Shaaban, Asmaa
- Philips, Mariana Victor
- Fayed, Ahmed
- Abdelaziz, Tarek Samy
- SpringerLink (Online service)
Other Objects (12)
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients
Prediction of microalbuminuria from proteinuria in chronic kidney disease due to non-diabetic lifestyle-related diseases: comparison with diabetes
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
![Proteinuria : [mit] 18 tables](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Proteinuria : [mit] 18 tables
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence
The superiority of economists
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure
Proteinuria—take a closer look!
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients
Prediction of microalbuminuria from proteinuria in chronic kidney disease due to non-diabetic lifestyle-related diseases: comparison with diabetes
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Proteinuria : [mit] 18 tables
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence
The superiority of economists
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure
Proteinuria—take a closer look!
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients
Prediction of microalbuminuria from proteinuria in chronic kidney disease due to non-diabetic lifestyle-related diseases: comparison with diabetes
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Proteinuria : [mit] 18 tables
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence
The superiority of economists
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure